|
Patient-related factor
|
|
Age (per 1 year)
|
1.02 (1.00–1.03)
|
0.098
| | |
|
Sex (Male vs. Female)
|
0.30 (0.18–0.47)
|
<.001
|
0.33 (0.19–0.55)
|
<.001
|
|
KPS
|
|
(80 vs. ≤70)
|
0.90 (0.53–1.56)
|
0.716
| | |
|
(≥90 vs. ≤70)
|
0.54 (0.30–0.97)
|
0.038
| | |
|
Baseline TLC (< 1000/μL vs. ≥1000/μL)
|
1.83 (1.09–3.07)
|
0.021
|
1.69 (0.94–3.03)
|
0.082
|
|
Tumor-related factor
|
|
Extent of resection
|
|
(Subtotal/Partial vs. Total)
|
2.85 (1.75–4.64)
|
<.001
|
2.40 (1.40–4.11)
|
0.001
|
|
(Biopsy vs. Total)
|
1.57 (0.62–3.94)
|
0.338
|
2.43 (0.84–6.98)
|
0.100
|
|
IDH1 mutation
|
|
(Yes vs. No)
|
0.64 (0.21–2.01)
|
0.447
|
0.75 (0.22–2.57)
|
0.649
|
|
(Unknown vs. No)
|
2.68 (1.56–4.64)
|
<.001
|
1.83 (0.93–3.62)
|
0.079
|
|
MGMT (Methylated vs. Unmethylated)
|
0.69 (0.43–1.11)
|
0.122
| | |
|
Subventriclular zone (Involved vs. Uninvolved)
|
1.27 (0.80–2.00)
|
0.308
| | |
|
Treatment-related factor
|
|
The cumulative dose of temozolomide (per 100 mg/m2)
|
0.98 (0.97–1.00)
|
0.087
|
0.99 (0.97–1.02)
|
0.530
|
|
PTV1 volume (per 10 cm3)
|
1.02 (1.00–1.03)
|
0.012
|
1.02 (1.00–1.03)
|
0.042
|
|
PTV2 volume (per 10 cm3)
|
1.02 (1.00–1.05)
|
0.083
| | |
|
Radiotherapy modality (IMRT vs. 3D-CRT)
|
0.32 (0.19–0.51)
|
<.001
|
0.48 (0.27–0.87)
|
0.015
|
|
Total dose (per 1 Gy)
|
0.95 (0.89–1.01)
|
0.072
| | |
|
No. of fractionation (per 1)
|
0.99 (0.90–1.08)
|
0.749
| | |
